Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28196643 | 0.80 | CYP3A4 (0.59) | CYP3A4CYP1A2CYP2C9CYP2C19LOXL2 | |
| SCHEMBL8513064 | 0.76 | CYP3A4 (0.55) | CYP3A4CYP1A2CYP2C9CYP2C19LOXL2 | |
| SCHEMBL27771941 | 0.76 | CYP3A4 (0.55) | CYP3A4CYP1A2CYP2C9CYP2C19LOXL2 | |
| SCHEMBL4690574 | 0.76 | CYP3A4 (0.45) | CYP3A4CYP1A2CYP2C9CYP2C19LOXL2 | |
| SCHEMBL27488305 | 0.75 | EPHX1 (0.50) | CYP1A2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL27539876 | 0.75 | EPHX1 (0.50) | CYP1A2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1007428 | 0.75 | EPHX1 (0.50) | CYP1A2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5495226 | 0.74 | SLC6A4 (0.50) | CYP3A4CYP1A2CYP2C9CYP2C19LOXL2 | |
| Hydrochloric Acid SCHEMBL11312932 | 0.74 | CYP3A4 (0.53) | CYP3A4CYP1A2CYP2C9CYP2C19LOXL2 | |
| SCHEMBL4272251 | 0.73 | TAAR1 (0.52) | CYP3A4CYP1A2CYP2C9CYP2C19SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| EP-2368877-B1 | Peptidomimetic protease inhibitors and intermediates for their preparation As treatment for HCV infection | VERTEX PHARMA (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-1958956-B1 | Peptidomimetic protease inhibitors | VERTEX PHARMA (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| EP-1320540-B9 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMA (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| EP-2371839-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| EP-2155711-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | Sanofi-Aventis (FR) | 2010-02-24 | — | — | EP | disclosed |
| EP-1320540-B1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMA (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008151211-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
| EP-1958956-A2 | Peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1878720-A1 | Process for preparing chiral bicycloprolinates as intermediates for the preparation of peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1849797-A2 | Peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20050197299-A1 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED | 2005-09-08 | — | — | US | disclosed |
| EP-1320540-A2 | PEPTIDOMIMETIC PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002018369-A2 | PEPTIDOMIMETIC PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197299-A1 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | CTRC, PEPD, CTSC | CYP3A4 133/4885CYP1A2 473/4885CYP2C9 93/4885 |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | CYP3A4 989/4885CYP1A2 1148/4885CYP2C9 943/4885 |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | CYP3A4 989/4885CYP1A2 1148/4885CYP2C9 943/4885 |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | CXCR5, CXCR1, CCR5 | CYP3A4 3828/4885CYP1A2 2835/4885CYP2C9 1961/4885 |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PEPD, PREP | CYP3A4 1121/4885CYP1A2 1860/4885CYP2C9 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.